506 related articles for article (PubMed ID: 15713947)
1. COX-2 inhibitors--a lesson in unexpected problems.
Drazen JM
N Engl J Med; 2005 Mar; 352(11):1131-2. PubMed ID: 15713947
[No Abstract] [Full Text] [Related]
2. COX-2 inhibitors--lessons in drug safety.
Psaty BM; Furberg CD
N Engl J Med; 2005 Mar; 352(11):1133-5. PubMed ID: 15713946
[No Abstract] [Full Text] [Related]
3. Coxibs and cardiovascular disease.
Fitzgerald GA
N Engl J Med; 2004 Oct; 351(17):1709-11. PubMed ID: 15470192
[No Abstract] [Full Text] [Related]
4. Raising the safety bar--the FDA's coxib meeting.
Okie S
N Engl J Med; 2005 Mar; 352(13):1283-5. PubMed ID: 15800221
[No Abstract] [Full Text] [Related]
5. Drug safety. FDA panel urges caution on many anti-inflammatory drugs.
Couzin J
Science; 2005 Feb; 307(5713):1183-5. PubMed ID: 15731414
[No Abstract] [Full Text] [Related]
6. The coxibs, selective inhibitors of cyclooxygenase-2.
FitzGerald GA; Patrono C
N Engl J Med; 2001 Aug; 345(6):433-42. PubMed ID: 11496855
[No Abstract] [Full Text] [Related]
7. COX-2 inhibitors and cardiovascular toxicity: a class effect?
Laible B
S D J Med; 2005 Mar; 58(3):93-4. PubMed ID: 15794479
[No Abstract] [Full Text] [Related]
8. The new COX-2 inhibitors: rofecoxib (Vioxx) and celecoxib (Celebrex).
Wynn RL
Gen Dent; 2000; 48(1):16-20. PubMed ID: 11199547
[No Abstract] [Full Text] [Related]
9. The COX-2 inhibitors--an update.
Furberg CD
Am Heart J; 2006 Aug; 152(2):197-9. PubMed ID: 16875896
[No Abstract] [Full Text] [Related]
10. COX-2 selective non-steroidal anti-inflammatory drugs and cardiovascular disease.
Ray WA; MacDonald TM; Solomon DH; Graham DJ; Avorn J
Pharmacoepidemiol Drug Saf; 2003; 12(1):67-70. PubMed ID: 12616850
[No Abstract] [Full Text] [Related]
11. Differences between COX-2-specific inhibitors: clinical and economic implications.
Sonnenblick EH
Am J Manag Care; 2002 Oct; 8(15 Suppl):S428-30. PubMed ID: 12416792
[No Abstract] [Full Text] [Related]
12. COX-2 inhibitors: no pain, no heart gain?
Harv Heart Lett; 2001 Dec; 12(4):2-4. PubMed ID: 11751079
[No Abstract] [Full Text] [Related]
13. [Gastric protective pain therapy. What is the advantage of new COX-2 inhibitors?].
Hinz B; Brune K
MMW Fortschr Med; 2000 Mar; 142(11):39-40. PubMed ID: 10786088
[No Abstract] [Full Text] [Related]
14. COX-2 inhibitors: cancer prevention or cardiovascular risk?
Senior K
Lancet Oncol; 2005 Feb; 6(2):68. PubMed ID: 15704289
[No Abstract] [Full Text] [Related]
15. [New anti-inflammatory analgetics--are they needed?].
Paakkari I
Duodecim; 1999; 115(20):2217-24. PubMed ID: 11973925
[No Abstract] [Full Text] [Related]
16. COX-2 inhibitors: better than traditional NSAIDs? Vioxx and Celebrex may be no less risky than NSAIDs.
Atkinson HG
Health News; 2002 Aug; 8(8):5. PubMed ID: 12206146
[No Abstract] [Full Text] [Related]
17. COX-2 inhibitors: new drugs for the management of pain and inflammation.
Hutchins V; Hutchins B
Dent Today; 2001 Feb; 20(2):56-61. PubMed ID: 12524847
[No Abstract] [Full Text] [Related]
18. Cyclooxygenase inhibition and adverse remodeling during healing after myocardial infarction.
Jugdutt BI
Circulation; 2007 Jan; 115(3):288-91. PubMed ID: 17242292
[No Abstract] [Full Text] [Related]
19. [Specific inhibitors of cyclooxygenase type 2] ].
Tomasová-Studýnková J
Vnitr Lek; 2002 May; 48(5):403-8. PubMed ID: 12061207
[TBL] [Abstract][Full Text] [Related]
20. Tailoring arthritis therapy in the wake of the NSAID crisis.
Olsen NJ
N Engl J Med; 2005 Jun; 352(25):2578-80. PubMed ID: 15972863
[No Abstract] [Full Text] [Related]
[Next] [New Search]
